NewsBenzingaBTIG ribadisce il giudizio Buy su Bicara Therapeutics, mantiene il target di prezzo a 39 $ BTIG ribadisce il giudizio Buy su Bicara Therapeutics, mantiene il target di prezzo a 39 $ Benzinga 2026.10.19 09:56 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning GE Aerospace Stock In The Last 5 Years Here's How Much $100 Invested In Allstate 15 Years Ago Would Be Worth Today Zions Bancorp Q3 2026 Earnings Call Transcript Here’s How Much You Would Have Made Owning Baidu Stock In The Last 20 Years Here’s How Much You Would Have Made Owning Plexus Stock In The Last 5 Years Canaccord Genuity Maintains Buy on Etoro Group, Lowers Price Target to $47
